Given that aberrant apoptotic mechanisms are often linked to chemo-resistance [37, 38], targeting LTB4R could lead to novel intervention strategies applicable beyond CRC to other malignancies like ovarian and breast cancers. Here, LTB4R is linked to breast carcinoma.